National Institutes of Health Pathways to Prevention Workshop: Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention.
Biomedical Research
Bone Density Conservation Agents
/ adverse effects
Decision Making, Shared
Denosumab
/ adverse effects
Diphosphonates
/ adverse effects
Duration of Therapy
Evidence-Based Medicine
Female
Humans
National Institutes of Health (U.S.)
Osteoporotic Fractures
/ prevention & control
Patient Acceptance of Health Care
Risk Assessment
United States
Journal
Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351
Informations de publication
Date de publication:
02 07 2019
02 07 2019
Historique:
pubmed:
23
4
2019
medline:
19
2
2020
entrez:
23
4
2019
Statut:
ppublish
Résumé
On 30 and 31 October 2018, the National Institutes of Health convened the Pathways to Prevention (P2P) Workshop: Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention to assess the available evidence on long-term (>3 years) use of drug therapies to prevent osteoporotic fractures and identify research gaps and needs for advancing the field. The workshop was cosponsored by the NIH Office of Disease Prevention (ODP), National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute on Aging. A multidisciplinary working group developed the agenda, and an Evidence-based Practice Center prepared an evidence report through a contract with the Agency for Healthcare Research and Quality to facilitate the discussion. During the 1.5-day workshop, invited experts discussed the body of evidence and attendees had the opportunity to comment during open discussions. After data from the evidence report, expert presentations, and public comments were weighed, an unbiased independent panel prepared a draft report that was posted on the ODP Web site for 5 weeks for public comment. This final report summarizes the panel's findings and recommendations. Current gaps in knowledge are highlighted, and a set of recommendations for new, strengthened research to better inform the long-term use of osteoporotic drug therapies is delineated.
Identifiants
pubmed: 31009943
pii: 2731606
doi: 10.7326/M19-0961
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Denosumab
4EQZ6YO2HI
Types de publication
Consensus Development Conference, NIH
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-57Commentaires et corrections
Type : ErratumIn